Throat carriage with methicillin-resistant Staphylococcus aureus: a cohort study on the effectiveness of topical eradication treatment Authors: Kristoffer Koch, Anne Kathrine Schultz Christensen, Niels Henrik Bruun, Pernille Ripadal Published: 2025 ABSTRACT BackgroundEradication treatment of methicillin-resistant Staphylococcus aureus (MRSA) carriers is an effective strategy to reduce transmission and infection rates. However, throat carriage is associated with treatment failure, and the optimal treatment for these patients remains uncertain. This study evaluated the effectiveness of topical eradication treatment in a cohort of patients with throat carriage and identified risk factors for treatment failure.MethodsThis population-based cohort study included residents of the North Denmark Region with first-time MRSA throat carriage between January 1, 2017, and December 31, 2020. Exclusions included patients under two years of age, those with occupational livestock exposure, and patients receiving systemic antimicrobial treatment. Successful eradication was defined as being MRSA-free six months after one or two topical treatment courses. Multivariable analysis assessed risk factors for treatment failure, including selected patient, environmental, and strain-related factors.ResultsOf 319 MRSA throat carriers, 258 completed the follow-up test six month after treatment. Among patients who completed follow-up, the overall eradication success rate was 43.4%. Throat carriers without additional risk factors for treatment failure achieved a 54.7% success rate, while those with additional risk factors had success rates ranging from 28.6% to 55.6%, depending on specific risk factors. Throat carriage combined with younger age, colonization by non-CC398 MRSA strains, and having MRSA-positive household members were associated with treatment failure.ConclusionsInitial topical treatment may be appropriate for MRSA throat carriers without additional risk factors, with over half achieving long-term eradication. This approach is especially relevant given the potential adverse effects of systemic antibiotics.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13756-025-01682-8. Background Methicillin-resistant Staphylococcus aureus (MRSA) refers to staphylococci resistant to beta-lactam antibiotics (i.e. penicillins, cephalosporins, carbapenems), necessitating the use of more costly, broad-spectrum antibiotics with greater risk of adverse effects [1]. MRSA colonization is associated with an increased risk of infections, ranging from minor skin infections to life-threatening bacteremia [2, 3]. In Europe, MRSA prevalence varies widely between countries, which may be due to differences in antibiotic use and national strategies to reduce MRSA incidence [4, 5]. In Denmark, the Danish Health Authority issued national MRSA guidelines in 2006, with updates in 2012 and 2016 [6]. These guidelines aim to reduce MRSA spread and maintain low infection rates through a “search-and-destroy” strategy, which includes screening high-risk patients in healthcare settings, isolating carriers, contact tracing, and initiating eradication treatment for MRSA carriers. In Denmark, the standard topical eradication treatment includes mupirocin nasal ointment and daily chlorhexidine body washes, concurrent with home eradication measures. Previous randomized controlled trials have shown that this regimen achieves approximately 60% efficacy in long-term eradication compared to placebo [7–10]. However, lower eradication success rates have been reported in MRSA carriers with throat carriage compared to those without. [11, 12] This led the Danish Health Authority to recommend considering supplementing with systemic antibiotic treatment after two unsuccessful topical treatment attempts, although the optimal treatment strategy for MRSA throat carriage remains unclear [13, 14]. According to the Dutch national guidelines, throat carriage is classified as a complicated carrier state, for which systemic antibiotic therapy is recommended without prior monotherapy with topical treatment [15]. Evidence on the effectiveness of topical eradication treatment for MRSA throat carriage is limited. Existing studies are limited by lack of population-based design, small sample sizes, inclusion of mixed patient populations, and absence of long-term follow-up [11, 12, 16–18]. To address these gaps, we conducted a population-based study to evaluate the long-term effectiveness of topical eradication treatment in an unselected cohort of patients with first-time MRSA throat carriage, without the administration of additional systemic antibiotic therapy. We also assessed individual risk factors associated with treatment failure in this population. Methods Study design and setting We conducted this cohort study among patients identified with first-time MRSA carriage between 1 January 2017 and 31 December 2020. We required that patients were living in the North Denmark Region at the time of diagnosis. The North Denmark Region has approximately 600,000 citizens (9.9% of Denmark’s population), which is the catchment population of the region’s local MRSA unit at Aalborg University Hospital. The region exhibits a low MRSA prevalence, constituting < 2% of Staphylococcus aureus in clinical samples, and mupirocin resistance among MRSA isolates remains rare (< 1%) [19, 20]. During the study period 95% of identified MRSA patients were referred and treated at the regional MRSA unit. To ensure a high referral rate, the test-ordering clinician was initially contacted by phone, followed by a letter if contact could not be established. Since 2017, all MRSA patients, resident in the North Denmark Region and treated at the MRSA unit, have been recorded prospectively in a regional MRSA surveillance and treatment database. Key information includes the patient’s civil registration number, date of the first positive MRSA sample, demographics, colonization/infection site, place of acquisition, number of household carriers, microbiology results, eradication treatments, and outcomes. Place of acquisition is categorized as community acquired, hospital acquired, imported or livestock associated. Assessment of acquisition was based on all available clinical, epidemiological and microbiological data. Variables related to eradication treatment failure were selected a priori, based on existing literature. In Denmark, all citizens are assigned a unique Civil Registration number at birth or upon immigration. This enables unambiguous individual-level data linkage between the MRSA database and other medical registries [21]. The tax-financed healthcare system provides free treatment, including topical and systemic antibiotics, for MRSA patients. MRSA screening In the North Denmark Region, MRSA screening targets individuals at high risk of carriage or infection, identified through a standardized risk assessment. Both symptomatic and asymptomatic individuals may be screened. All hospital admissions and elective surgical patients are screened using a questionnaire based on the Danish national MRSA guidelines. Major risk factors include previous MRSA infection or carriage, household contact with MRSA-positive individuals, hospitalization or treatment outside the Nordic countries, and regular contact with live pigs within the past six months. Testing is also recommended for patients with symptomatic staphylococcal infections and relevant risk exposures, as well as for suspected staphylococcal infections unresponsive to standard treatment. Samples are routinely collected from the nose, throat, and perineum. Additional samples are recommended from wounds, skin lesions, catheter urine, device insertion sites (e.g., tubes or drains), and any previously MRSA-positive sites [6]. Microbiological laboratory methods Each screening sample underwent individual processing, i.e., no samples were pooled. Samples were incubated for 18–24 h in enrichment broth (Tryptic Soy Broth, Becton Dickinson) and subsequently plated on selective MRSA agar (CHROMagar™ MRSA II, Becton Dickinson). MRSA colonies were identified using MALDI-TOF MS (Bruker Daltonics, Microflex LT Biotyper). Subsequent antimicrobial susceptibility testing was conducted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standardized disk diffusion method using Thermo Scientific™ Oxoid™ discs. Methicillin resistance was screened with a cefoxitin disc and confirmed using the Xpert® MRSA NxG test on the GeneXpert® Dx System (Cepheid). All isolates underwent testing for mupirocin resistance, including isolates obtained from multiple sites or at different timepoints from the same patient. Presumed MRSA colonies detected in clinical samples were processed similarly to screening samples. The MRSA isolates were forwarded to the National Reference Laboratory for Antimicrobial Resistance at Statens Serum Institut for comprehensive genotypic characterization, including multilocus sequence typing (MLST), clonal complex (CC) assignment, and detection of Panton-Valentine leucocidin (PVL) genes, among others. Exclusion criteria Individuals residing in the North Denmark Region who were diagnosed with MRSA during the study period were eligible for inclusion. Exclusion criteria were applied sequentially and included prior MRSA diagnosis, diagnosis with livestock-associated MRSA (CC398) with ongoing exposure, age under 2 years, refusal of treatment, residency outside the catchment area, absence of MRSA colonization or throat carriage upon screening at the MRSA unit, or concurrent systemic antibiotic treatment with the topical treatment. These criteria were consistent with the Danish national MRSA guideline, which does not recommend eradication in individuals colonized with livestock-associated MRSA and in regular contact with livestock, due to persistent exposure and a high risk of recolonization. In Denmark, livestock-associated MRSA is primarily linked to pig farming. The guideline also advises against eradication in newborns and children younger than 2 years, given the low success rate in this population and the potential for chlorhexidine-associated skin injury in neonates. Some patients presented with active MRSA infections at baseline or during follow-up at the MRSA unit. Those receiving systemic antibiotic treatment were excluded, as the study aimed to assess the effect of topical eradication treatment alone. Eradication treatment According to the Danish national MRSA guideline, standard eradication treatment consists of 5 days of 2% mupirocin nasal ointment applied to both nares twice daily, combined with full-body washing using 4% chlorhexidine soap. For individuals with MRSA throat carriage, the guideline recommends extending this regimen to 10 days. Due to the potential risk of side effects associated with systemic antibiotics, the guideline further recommends completing two courses of topical treatment before considering systemic treatment. MRSA throat carriers included in this study received the recommended 10-day regimen of 2% mupirocin nasal ointment and daily chlorhexidine body washing. Consistent with national guideline recommendations, participants were also advised to undertake concurrent environmental decontamination at home, including daily laundering of clothes, surface cleaning, and changing of bed linens and towels. Contrary to national recommendations, eradication treatment was initiated regardless of the presence of wounds, indwelling foreign bodies (e.g. urinary catheters, drains, PEG tubes), or chronic skin conditions. These comorbidities were managed in parallel with eradication treatment and, when necessary, involved consultation with a dermatologist or wound care teams. Since transmission is common within households, all household members were screened for MRSA using samples from routine screening sites (nose, throat, and perineum), supplemented with additional samples as required by the standard screening procedure. To prevent ongoing transmission, all MRSA-positive individuals within a household received topical eradication treatment simultaneously. Household members who were not MRSA throat carriers received 5 days of standard topical treatment, whereas throat carriers received 10 days. MRSA-positive household members with positive throat samples at the initial screening were eligible for study inclusion. After the first course of topical treatment, all MRSA-positive household members underwent simultaneous follow-up sampling, with the first control sample collected one month after treatment completion. Those who remained positive were offered a second course of topical treatment and subsequent follow-up sampling. Patients were managed through an open outpatient course at the regional MRSA unit, which remained available for consultations related to adverse events or treatment concerns. All topical treatment was provided free of charge by the MRSA unit’s outpatient clinic. Most patients were referred by their general practitioner and received treatment at the outpatient clinic. A smaller proportion were identified as MRSA throat-positive for the first time during hospital admission at one of the region’s hospitals. In these cases, topical treatment was initiated during hospitalization following telephone consultation with the MRSA unit or via an in-person visit from an MRSA unit hygiene nurse. Adherence to topical treatment was assessed during telephone contact with patients when follow-up swab results were communicated. Patients were also encouraged to contact the MRSA unit if they experienced any side effects. All side effects and deviations from the treatment were recorded. Outcome and follow-up Successful eradication treatment was assessed based on whether the patient was declared MRSA-free following the completion of their treatment. In line with national criteria MRSA-free was defined as having two consecutive negative cultures from the nose, throat, perineum, and any previously positive sites. The first culture should be obtained at least one month after treatment completion, and the final culture at least six months after treatment. Patients were followed from the initiation of the first topical treatment until the occurrence of one of the following endpoints: MRSA eradication, persistence of MRSA after two topical treatments, or loss to follow-up (including death), whichever came first. Statistical analysis Descriptive statistics included frequencies and proportions for categorical variables and medians with interquartile range (IQR) for continuous variables. Patient-, environmental- and strain-related characteristics among patients with and without treatment failure were summarized in a contingency table. Correlations between variables were visualized in a heat plot based on Pearson correlations. We used logistic regression to calculate univariate odds ratios (ORs) with 95% confidence intervals (CIs) to assess the relative risks of treatment failure according to patient-, environmental-, and strain-related characteristics. A LASSO (least absolute shrinkage and selection operator) model with cross-validation as optimization was applied to identify key predictors of treatment failure. Odds ratios for treatment failure associated with the predictors identified in the LASSO model were subsequently calculated using logistic regression, including all variables. All analyses were conducted using data from patients with complete follow-up. Successful eradication rates were calculated after the first and second treatment attempts, along with a cumulative eradication rate. Analyses were performed for the intention-to-treat (ITT) and per protocol populations, as well as for patients with complete follow-up. The ITT population included all patients in the final study cohort who initiated topical treatment, while the per protocol population comprised those who completed treatment according to the national MRSA guideline. Patients with missing follow-up were considered not successfully eradicated in both ITT and per protocol analyses. To account for incomplete follow-up, a sensitivity analysis estimated a range for the true success rate by assuming patients lost to follow-up were either MRSA-free or still MRSA-positive. In subgroup analyses, we assessed eradication rates among throat-only carriers and patients with additional risk factors for treatment failure. Stata version 18 for Windows (Stata Corp, Texas, USA) was used for data analyses. Results During the study period, 2157 patients were tested positive for MRSA. Most patients were excluded from the final study cohort due to prior MRSA positivity, colonization with livestock-associated MRSA with ongoing exposure, or negative throat swabs upon screening (Fig. 1). The final cohort included 319 first-time MRSA throat carriers, over 2 years old, residing in the North Denmark Region, eligible for topical eradication treatment and not receiving systemic antibiotic at time of enrolment. Mupirocin-resistant MRSA strains was not detected in any patients at baseline or after the first or second topical treatments.Fig. 1Study flow diagram summarizing inclusion and exclusion of patients Study flow diagram summarizing inclusion and exclusion of patients Cohort characteristics of throat carriers Among the 319 patients subjected to topical eradication treatment, 61 (19.1%) patients were lost to follow-up during the long-term assessment six months after treatment, leaving 258 patients with complete follow-up data. Reasons for loss to follow-up included unknown causes (42; 69%), declining further treatment and control examinations after first treatment attempt (11; 17%), and relocation from the region (4; 7%) or death (4; 7%). Among patients with throat carrier state and complete follow-up, the median age was 27.0 (IQR: 15.0; 39.0) years, with 62.0% female and 72.5% of Danish ethnicity (see Supplementary Table S1). A large proportion (41.9%) had CC398 MRSA strains, reflecting the high prevalence of pig farmers in the region. Most patients acquired MRSA domestically (74.4%), with an equal distribution between livestock-associated and community-acquired MRSA. Others acquired MRSA abroad (21.3%) or during hospitalization (4.3%). Several patient-, environmental- and strain-related characteristics were correlated (see Supplementary Figure S1). Non-Danish ethnicity correlated with MRSA acquired abroad, with 46.5% (33/71) of patients with non-Danish ethnicity acquiring their MRSA strains abroad. These strains exhibited a higher frequency of PVL positivity (34,5%; 19/55). Non-Danish ethnicity also correlated positively with having more MRSA-positive household members (45.1% [32/71] had 2 or more MRSA-positive household members). Hospital-acquired MRSA correlated with older age and MRSA detected in skin lesions. Comparison of patient characteristics between unsuccessful and successful MRSA eradication groups Compared to patients with successful MRSA eradication, those with unsuccessful eradication were more often male, younger, and more likely to be of non-Danish ethnicity (Table 1).Table 1Characteristics of 258 MRSA throat carriers with complete follow-up with successful or unsuccessful eradication 6 months after completion of topical treatment, North Denmark Region, 2017–2020Characteristics at time of enrollmentSuccessful MRSA eradicationN = 112 (43.4%)Unsuccessful MRSA eradicationN = 146 (56.6%)Sex, males, n (%)37 (33.0)61 (41.8)Age, years, median (IQR)28.5 (23.0–42.0)24.5 (10.0–38.0)Age group, n (%)2–19 yr22 (19.6)55 (37.9)20–39 yr59 (52.7)59 (40.7)40–59 yr16 (14.3)16 (11.0) ≥ 60 yr15 (13.4)15 (10.3)Ethnicity (Danish), n (%)86 (76.8)101 (69.2)Positive household members, n (%)042 (37.5)42 (28.8)145 (40.2)44 (30.1) ≥ 225 (22.3)60 (41.1)Place of MRSA acquisition, n (%)Community acquired39 (34.8)57 (39.0)Hospital acquired3 (2.7)8 (5.5)Imported16 (14.3)39 (26.7)Livestock associated54 (48.2)42 (28.8)Sites other than the throat testing positive for MRSA, n (%)Nose65 (58.0)85 (58.2)Perineum30 (26.8)33 (22.6)Skin lesions (wounds, eczema, psoriasis)14 (12.5)23 (15.8)Strain related characteristics, n (%)CC39860 (53.6)48 (32.9)PVL positive8 (7.1)20 (13.7)MRSA: methicillin resistant Staphylococcus aureus; IQR: interquartile range; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leukocidin Table 1Characteristics of 258 MRSA throat carriers with complete follow-up with successful or unsuccessful eradication 6 months after completion of topical treatment, North Denmark Region, 2017–2020Characteristics at time of enrollmentSuccessful MRSA eradicationN = 112 (43.4%)Unsuccessful MRSA eradicationN = 146 (56.6%)Sex, males, n (%)37 (33.0)61 (41.8)Age, years, median (IQR)28.5 (23.0–42.0)24.5 (10.0–38.0)Age group, n (%)2–19 yr22 (19.6)55 (37.9)20–39 yr59 (52.7)59 (40.7)40–59 yr16 (14.3)16 (11.0) ≥ 60 yr15 (13.4)15 (10.3)Ethnicity (Danish), n (%)86 (76.8)101 (69.2)Positive household members, n (%)042 (37.5)42 (28.8)145 (40.2)44 (30.1) ≥ 225 (22.3)60 (41.1)Place of MRSA acquisition, n (%)Community acquired39 (34.8)57 (39.0)Hospital acquired3 (2.7)8 (5.5)Imported16 (14.3)39 (26.7)Livestock associated54 (48.2)42 (28.8)Sites other than the throat testing positive for MRSA, n (%)Nose65 (58.0)85 (58.2)Perineum30 (26.8)33 (22.6)Skin lesions (wounds, eczema, psoriasis)14 (12.5)23 (15.8)Strain related characteristics, n (%)CC39860 (53.6)48 (32.9)PVL positive8 (7.1)20 (13.7)MRSA: methicillin resistant Staphylococcus aureus; IQR: interquartile range; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leukocidin Characteristics of 258 MRSA throat carriers with complete follow-up with successful or unsuccessful eradication 6 months after completion of topical treatment, North Denmark Region, 2017–2020 MRSA: methicillin resistant Staphylococcus aureus; IQR: interquartile range; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leukocidin There was no notable difference between the unsuccessful and successful MRSA eradication groups in MRSA positivity at other screening sites (nose and perineum). However, a slightly higher proportion of patients with unsuccessful eradication had positive MRSA samples from skin lesions. Patients with unsuccessful eradication were at higher risk of recolonization during the treatment period. This increased risk stemmed from a notable larger proportion of patients in the unsuccessful eradication group having two or more MRSA-positive household members compared to the successful eradication group (41.1% vs. 22.3%). Regarding MRSA strain characteristics, patients with unsuccessful eradication had higher proportions of non-CC398 MRSA strains, PVL-positive MRSA strains, and MRSA strains acquired abroad compared to those with successful eradication. Prediction of unsuccessful MRSA eradication Table 2 shows the univariate risk analysis findings. Young age (age group 2–19 years) (OR, 2.50; 95% CI 1.35–4.62; P < 0.005), carrying a non-CC398 MRSA strain (OR, 2.36; 95% CI 1.42–3.92; P < 0.005), acquiring MRSA abroad (OR, 3.13; 95% CI 1.54–6.37; P < 0.005), and having two or more positive household members (OR, 2.40; 95% CI 1.27–4.53; P = 0.01) were all significant predictors of unsuccessful MRSA eradication after two topical treatments.Table 2Univariate analysis of risk factors for unsuccessful MRSA eradication 6 months after topical treatment completion, North Denmark Region, 2017–2020VariableOdds ratio (95% CI)P-valuesSexFemale1.00 (ref.)Male1.45 (0.87–2.43)0.15Age group2–19 yr2.50 (1.35–4.62) < .00520–39 yr1.00 (ref.)40–59 yr1.00 (0.46–2.19)1.00 ≥ 60 yr1.00 (0.45–2.23)1.00EthnicityDanish1.00 (ref.)Non-Danish1.47 (0.84–2.59)0.18Positive household members01.00 (ref.)10.98 (0.54–1.78)0.94 ≥ 22.40 (1.27–4.53)0.01Place of MRSA acquisitionLivestock associated1.00 (ref.)Community acquired1.88 (1.06–3.34)0.03Hospital acquired3.43 (0.85–13.76)0.08Imported3.13 (1.54–6.37) < .005Sites other than the throat testing positive for MRSANose (no)1.00 (ref.)Nose (yes)1.01 (0.61–1.66)0.98Perineum (no)1.00 (ref.)Perineum (yes)0.80 (0.45–1.41)0.44Skin lesions* (no)1.00 (ref.)Skin lesions (yes)1.31 (0.64–2.68)0.46Strain related charcteristicsCC3981.00 (ref.)Non-CC3982.36 (1.42–3.92) < .005PVL-negative1.00 (ref.)PVL-positive2.06 (0.87–4.88)0.10MRSA: methicillin resistant Staphylococcus aureus; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leucocidin*Skin lesions included wounds, eczema and psoriasis Table 2Univariate analysis of risk factors for unsuccessful MRSA eradication 6 months after topical treatment completion, North Denmark Region, 2017–2020VariableOdds ratio (95% CI)P-valuesSexFemale1.00 (ref.)Male1.45 (0.87–2.43)0.15Age group2–19 yr2.50 (1.35–4.62) < .00520–39 yr1.00 (ref.)40–59 yr1.00 (0.46–2.19)1.00 ≥ 60 yr1.00 (0.45–2.23)1.00EthnicityDanish1.00 (ref.)Non-Danish1.47 (0.84–2.59)0.18Positive household members01.00 (ref.)10.98 (0.54–1.78)0.94 ≥ 22.40 (1.27–4.53)0.01Place of MRSA acquisitionLivestock associated1.00 (ref.)Community acquired1.88 (1.06–3.34)0.03Hospital acquired3.43 (0.85–13.76)0.08Imported3.13 (1.54–6.37) < .005Sites other than the throat testing positive for MRSANose (no)1.00 (ref.)Nose (yes)1.01 (0.61–1.66)0.98Perineum (no)1.00 (ref.)Perineum (yes)0.80 (0.45–1.41)0.44Skin lesions* (no)1.00 (ref.)Skin lesions (yes)1.31 (0.64–2.68)0.46Strain related charcteristicsCC3981.00 (ref.)Non-CC3982.36 (1.42–3.92) < .005PVL-negative1.00 (ref.)PVL-positive2.06 (0.87–4.88)0.10MRSA: methicillin resistant Staphylococcus aureus; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leucocidin*Skin lesions included wounds, eczema and psoriasis Univariate analysis of risk factors for unsuccessful MRSA eradication 6 months after topical treatment completion, North Denmark Region, 2017–2020 MRSA: methicillin resistant Staphylococcus aureus; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leucocidin *Skin lesions included wounds, eczema and psoriasis In the multivariable analysis using LASSO regression for regularization, we identified decreasing age, carriage of a non-CC398 MRSA strain, and an increasing number of MRSA-positive household members as predictors of unsuccessful eradication following two treatment attempts. Odds ratios for unsuccessful eradication associated with the key predictors identified in the LASSO model were: 2.05 (95% CI 1.12–3.74; P = 0.02) for patients aged 2–19 years compared with those aged ≥ 20 years; 1.30 (95% CI 0.50–3.38; P = 0.59) for non-CC398 versus CC398 strains; and 1.22 (95% CI: 0.86–1.74; P = 0.25) per additional MRSA-positive household member. The model's overall predictive performance had an area under the ROC curve of 0.65 (95% CI: 0.58–0.71). Eradication success rates following topical treatment The vast majority of patients were either declared MRSA-free, found to be MRSA-positive after two topical treatment attempts, or lost to follow-up within one year of treatment initiation at the MRSA unit. Among those who achieved MRSA eradication, the median time from treatment initiation to confirmed MRSA freedom was 239 days (range: 193–583 days). Of the 319 patients undergoing topical MRSA eradication, 301 (94.4%) received treatment in accordance with national guidelines (Table 3). Among those who did not receive guideline-concordant treatment, 13 out of 18 (72.2%) received only 5 days of topical treatment.Table 3Analysis of eradication success rates after one or two topical treatment attempts in MRSA throat carriersFirst topical treatment attempt, n (%)Second topical treatment attempt, n (%)Total, n (%)Patients receiving topical treatment319 (100)177b (55.5)319 (100)Patients who received full standard topical treatment301 (94.4)a165 (93.2)c289 (90.6)Patients lost to follow-up43 (13.5)18 (10.2)61 (19.1)Successful MRSA eradication in the intention-to-treat population88 (27.6)24 (13.6)112 (35.1)Successful MRSA eradication in the per protocol population86 (28.6)21 (12.7)107 (37.0)Successful MRSA eradication in patients with complete follow-up88 (31.9)24 (15.1)112 (43.4)MRSA: methicillin resistant Staphylococcus aureusa Deviations from the standard topical treatment were observed: one patient underwent a three-day topical treatment regimen; Thirteen patients underwent a five-day topical treatment regimen; Two patients received only 2% mupirocin nasal ointment; Two patients underwent reduced treatment with chlorhexidine soap (< 4 days), but completed 10 days of 2% mupirocin ointmentb Nine patients received systemic treatment after their initial topical treatment attempt. Two patients declined further treatment after their first topical treatmentc Deviations from the standard topical treatment were observed: twelve patients tested positive exclusively for MRSA in throat swaps and consequently received only 2% mupirocin nasal ointment during their second treatment attempt Table 3Analysis of eradication success rates after one or two topical treatment attempts in MRSA throat carriersFirst topical treatment attempt, n (%)Second topical treatment attempt, n (%)Total, n (%)Patients receiving topical treatment319 (100)177b (55.5)319 (100)Patients who received full standard topical treatment301 (94.4)a165 (93.2)c289 (90.6)Patients lost to follow-up43 (13.5)18 (10.2)61 (19.1)Successful MRSA eradication in the intention-to-treat population88 (27.6)24 (13.6)112 (35.1)Successful MRSA eradication in the per protocol population86 (28.6)21 (12.7)107 (37.0)Successful MRSA eradication in patients with complete follow-up88 (31.9)24 (15.1)112 (43.4)MRSA: methicillin resistant Staphylococcus aureusa Deviations from the standard topical treatment were observed: one patient underwent a three-day topical treatment regimen; Thirteen patients underwent a five-day topical treatment regimen; Two patients received only 2% mupirocin nasal ointment; Two patients underwent reduced treatment with chlorhexidine soap (< 4 days), but completed 10 days of 2% mupirocin ointmentb Nine patients received systemic treatment after their initial topical treatment attempt. Two patients declined further treatment after their first topical treatmentc Deviations from the standard topical treatment were observed: twelve patients tested positive exclusively for MRSA in throat swaps and consequently received only 2% mupirocin nasal ointment during their second treatment attempt Analysis of eradication success rates after one or two topical treatment attempts in MRSA throat carriers MRSA: methicillin resistant Staphylococcus aureus a Deviations from the standard topical treatment were observed: one patient underwent a three-day topical treatment regimen; Thirteen patients underwent a five-day topical treatment regimen; Two patients received only 2% mupirocin nasal ointment; Two patients underwent reduced treatment with chlorhexidine soap (< 4 days), but completed 10 days of 2% mupirocin ointment b Nine patients received systemic treatment after their initial topical treatment attempt. Two patients declined further treatment after their first topical treatment c Deviations from the standard topical treatment were observed: twelve patients tested positive exclusively for MRSA in throat swaps and consequently received only 2% mupirocin nasal ointment during their second treatment attempt In the ITT analysis, the long-term eradication success rate after the first eradication attempt was 27.6% (88/319), compared with 28.6% (86/301) in the per protocol analysis. Not all eligible patients proceeded to a second treatment attempt. Among those who remained MRSA-positive after the first topical treatment attempt and were not lost to follow-up, two declined further treatment and nine received systemic antibiotic therapy during the second topical treatment attempt. A total of 177 patients underwent a second topical treatment course, of whom 165 (93.2%) were treated in accordance with guidelines. The success rate following the second treatment attempt was 13.6% (24/177) in the ITT population and 12.7% (21/165) in the per protocol population. The cumulative long-term eradication success rate was 35.1% (112/319) in the ITT population and 37.0% (107/289) in the per protocol population. A sensitivity analysis showed that the overall eradication success rate was 43.4% in patients with complete follow-up, with the estimated true rate ranging from 35,1% and 54,2% (see Supplementary Table S2). Subgroup analysis identified significantly higher eradication rates among patients with isolated throat carriage and no additional risk factors for treatment failure. Specifically, among patients with complete follow-up and without skin lesions, foreign bodies, or MRSA-positive household members, the eradication success rate was 54.7% (Table 4).Table 4Cumulative eradication rates after two topical treatments attempts in MRSA throat carriers, with or without other risk factors for unsuccessful eradicationPrimary characteristicsPatients treated with 1 or 2 topical treatments, nPatients with successful eradication*, n (%)Sex, male9837 (37.8)Sex, female16075 (46.9)Age 2–19 yr7722 (28.6)Age 20–39 yr11859 (50.0)Age 40–59 yr3216 (50.0)Age ≥ 60 yr3115 (48.4)Danish ethnicity18786 (46.0)Non-Danish ethnicity7126 (36.6)Throat carriers without other risk factors of unsuccessful eradication6435 (54.7)Throat carriers with skin lesions3714 (37.8)Throat carriers with foreign bodies10 (0.0)Throat carriers without positive household members8442 (50.0)Throat carriers with 1 positive household member8945 (50.6)Throat carriers with 2 or more positive household members8525 (29.4)Throat carriers with CC39810860 (55.6)Throat carriers with non-CC39815052 (34.7)Throat carriers with PVL-negative strain230104 (45.2)Throat carriers with PVL-positive strain288 (28.6)Throat carriers with nose colonization15065 (43.3)Throat carriers with perineum colonization6330 (47.6)MRSA: methicillin resistant Staphylococcus aureus; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leucocidin*Eradication rates in patients with complete follow-up Table 4Cumulative eradication rates after two topical treatments attempts in MRSA throat carriers, with or without other risk factors for unsuccessful eradicationPrimary characteristicsPatients treated with 1 or 2 topical treatments, nPatients with successful eradication*, n (%)Sex, male9837 (37.8)Sex, female16075 (46.9)Age 2–19 yr7722 (28.6)Age 20–39 yr11859 (50.0)Age 40–59 yr3216 (50.0)Age ≥ 60 yr3115 (48.4)Danish ethnicity18786 (46.0)Non-Danish ethnicity7126 (36.6)Throat carriers without other risk factors of unsuccessful eradication6435 (54.7)Throat carriers with skin lesions3714 (37.8)Throat carriers with foreign bodies10 (0.0)Throat carriers without positive household members8442 (50.0)Throat carriers with 1 positive household member8945 (50.6)Throat carriers with 2 or more positive household members8525 (29.4)Throat carriers with CC39810860 (55.6)Throat carriers with non-CC39815052 (34.7)Throat carriers with PVL-negative strain230104 (45.2)Throat carriers with PVL-positive strain288 (28.6)Throat carriers with nose colonization15065 (43.3)Throat carriers with perineum colonization6330 (47.6)MRSA: methicillin resistant Staphylococcus aureus; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leucocidin*Eradication rates in patients with complete follow-up Cumulative eradication rates after two topical treatments attempts in MRSA throat carriers, with or without other risk factors for unsuccessful eradication MRSA: methicillin resistant Staphylococcus aureus; yr: years; CC398: clonal complex 398; PVL: Panton-Valentine leucocidin *Eradication rates in patients with complete follow-up Side effects during topical treatment No patients experienced severe allergic reactions related to topical treatment. Five patients (1.6%) experienced minor side effects, all associated with chlorhexidine washing, including hair and skin drying and skin irritation. These side effects led to treatment discontinuation. Discussion In this cohort study of MRSA throat carriers, the long-term eradication success rate with topical treatment alone was 43.4% among patients with complete follow-up. Among patients with throat carriage but without skin lesions, foreign bodies, or at risk of recolonization from MRSA-positive household members, the success rate increased to 54.7%. Our study suggests that among patients with throat carriage, certain subgroups may not achieve successful eradication, including those of younger age, those colonized by non-CC398 MRSA strains, and those with MRSA-positive household members. Only few studies have specifically examined the long-term eradication of MRSA throat carriers. A small Swedish study of outpatients with MRSA throat carriage found that topical treatment achieved successful eradication in only 13% of patients six months post-treatment [16]. This study was conducted in a country with a low MRSA prevalence, comparable to Denmark. The significantly lower eradication rate observed with topical treatment in the Swedish study, compared to our findings, may be attributed to several factors. The study cohort was highly selected, comprising individuals with frequent healthcare contact, recurrent MRSA infections and healthcare personnel, unlike the unselected cohort in our study. Furthermore, patients had been MRSA carriers an extended period (an average of 1.2 years), and one-third had already undergone eradication treatment prior to inclusion. Additionally, patients received only 5 days of topical treatment, whereas as our study administered 10 days. The study documented that combining topical treatment and systemic antibiotics increased the eradication rate to 61%. Two previous Danish studies have examined long-term eradication success in diverse cohorts of MRSA carriers. In subgroup analyses of patients with throat carriage, these studies reported higher eradication rates of 62% and 73% in patients with complete follow-up, compared to our findings [12, 17]. However, direct comparison is difficult, as approximately one-third of patients in both study cohorts received combined topical and systemic antibiotic treatment. Additionally, patients in those studies underwent up to four treatment attempts, which likely contributed to the higher cumulative eradication rates observed. Our finding that younger age, colonization with non-CC398 strains, or having MRSA-positive household members were associated with lower eradication success rates among MRSA throat carriers aligns with previous studies on more diverse cohorts [11, 15, 18, 22, 23]. This suggests that the risk factors for unsuccessful eradication are consistent across different MRSA patient populations. However, our study highlights that the combination of throat carriage with additional risk factors is particularly linked to lower eradication success rates. The key strengths of our study are its setting within an equitable, tax-funded healthcare system that provides free access to treatment including both topical and systemic antibiotics for MRSA patients. This, together with the fact that 95% of patients identified as MRSA-positive during the study period were referred to and treated at the regional MRSA unit, enabled the inclusion of a large, unselected cohort of MRSA throat carriers. The main limitations of the study are the absence of a placebo control group and incomplete follow-up data for one-fifth of the cohort. However, we believe the patients included in the final cohort were persistent carriers of MRSA. This is supported by the fact that they consistently tested positive for MRSA during screening at the MRSA unit following earlier positive swaps from their general practitioners. Additionally, most patients were MRSA-positive at other sites (nose or perineum) besides the throat. Antibiotic susceptibility testing and genotyping further confirmed that the same MRSA strain was present over time. Thus, we argue that the success rates observed in the study reflect reliable estimates of the topical treatment’s efficacy. Another limitation is that we were unable to monitor patients’ adherence to the prescribed topical treatment beyond the information provided by the patients. Consequently, some patients may not have fully complied with the treatment, which could have led to an under estimation of the success rates. Conclusions In countries with a national MRSA guideline implementing a “search and destroy” strategy, eradication efforts must balance the societal benefit of maintaining low MRSA prevalence against the individual consequences of carriage, potential adverse effects of treatment, and the likelihood of successful eradication. Based on our study results, we propose that for patients with first-time MRSA throat carriage and without additional risk factors for eradication failure and no prior MRSA eradication treatment, initial treatment with one or two topical treatment attempts may be appropriate. This long-term eradication approach warrants consideration as an alternative to systemic antibiotics, which is associated with a higher risk of adverse effects and may contribute to antimicrobial resistance. Nevertheless, for individuals with concurrent risk factors, topical treatment alone may result in suboptimal eradication rates. In these cases, alternative treatment strategies, including systemic antibiotics, should be considered. Currently, there is a lack of prospective, randomized, placebo-controlled trials evaluating MRSA throat carriage treatment, either with standard topical eradication treatment alone or in combination with systemic antibiotics. Such trials are needed to strengthen the evidence base and clarify the role of systemic antibiotics in MRSA throat eradication. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1.